CA3104252A1 - Anti-l1cam antibodies and uses thereof - Google Patents

Anti-l1cam antibodies and uses thereof Download PDF

Info

Publication number: CA3104252A1
Authority: CA; Canada
Prior art keywords: antibody; antigen; seq; binding fragment; less
Prior art date: 2018-06-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3104252A

Other languages

English (en)

French (fr)

Inventor

Hyo Jeong Hong

Heesu CHAE

Jisu HONG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Apitbio Inc

Original Assignee

University Industry Cooperation Foundation of Kangwon National University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-29

Filing date

2019-06-27

Publication date

2020-01-02

2019-06-27 Application filed by University Industry Cooperation Foundation of Kangwon National University filed Critical University Industry Cooperation Foundation of Kangwon National University

2019-06-27 Priority claimed from PCT/IB2019/055472 external-priority patent/WO2020003210A1/en

2020-01-02 Publication of CA3104252A1 publication Critical patent/CA3104252A1/en

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 claims abstract description 142
206010028980 Neoplasm Diseases 0.000 claims abstract description 110
239000000203 mixture Substances 0.000 claims abstract description 45
201000010099 disease Diseases 0.000 claims abstract description 35
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
102000019009 Neural Cell Adhesion Molecule L1 Human genes 0.000 claims abstract 15
108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims abstract 15
230000027455 binding Effects 0.000 claims description 385
239000000427 antigen Substances 0.000 claims description 367
108091007433 antigens Proteins 0.000 claims description 364
102000036639 antigens Human genes 0.000 claims description 364
239000012634 fragment Substances 0.000 claims description 333
210000004027 cell Anatomy 0.000 claims description 212
241000282414 Homo sapiens Species 0.000 claims description 134
101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 84
102000047582 human L1CAM Human genes 0.000 claims description 84
150000001413 amino acids Chemical class 0.000 claims description 83
239000013598 vector Substances 0.000 claims description 83
235000001014 amino acid Nutrition 0.000 claims description 71
150000007523 nucleic acids Chemical class 0.000 claims description 49
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 46
102000039446 nucleic acids Human genes 0.000 claims description 43
108020004707 nucleic acids Proteins 0.000 claims description 43
239000003814 drug Substances 0.000 claims description 35
230000001976 improved effect Effects 0.000 claims description 31
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 28
229940127121 immunoconjugate Drugs 0.000 claims description 28
239000003795 chemical substances by application Substances 0.000 claims description 26
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 19
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 19
229940124597 therapeutic agent Drugs 0.000 claims description 19
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 18
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 15
210000001744 T-lymphocyte Anatomy 0.000 claims description 15
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 14
238000010494 dissociation reaction Methods 0.000 claims description 14
230000005593 dissociations Effects 0.000 claims description 14
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 14
210000001519 tissue Anatomy 0.000 claims description 13
239000004471 Glycine Substances 0.000 claims description 10
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
235000004279 alanine Nutrition 0.000 claims description 10
210000002865 immune cell Anatomy 0.000 claims description 10
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
230000012010 growth Effects 0.000 claims description 9
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
201000001441 melanoma Diseases 0.000 claims description 8
238000009169 immunotherapy Methods 0.000 claims description 7
206010006187 Breast cancer Diseases 0.000 claims description 6
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
239000004473 Threonine Substances 0.000 claims description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
239000004474 valine Substances 0.000 claims description 6
206010004593 Bile duct cancer Diseases 0.000 claims description 5
208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
206010033128 Ovarian cancer Diseases 0.000 claims description 5
206010038389 Renal cancer Diseases 0.000 claims description 5
208000026900 bile duct neoplasm Diseases 0.000 claims description 5
238000002512 chemotherapy Methods 0.000 claims description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
210000005260 human cell Anatomy 0.000 claims description 5
201000010982 kidney cancer Diseases 0.000 claims description 5
208000026310 Breast neoplasm Diseases 0.000 claims description 4
241000588724 Escherichia coli Species 0.000 claims description 4
208000032612 Glial tumor Diseases 0.000 claims description 4
206010018338 Glioma Diseases 0.000 claims description 4
241000238631 Hexapoda Species 0.000 claims description 4
206010025323 Lymphomas Diseases 0.000 claims description 4
206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
201000010897 colon adenocarcinoma Diseases 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
201000007270 liver cancer Diseases 0.000 claims description 4
208000014018 liver neoplasm Diseases 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
238000001959 radiotherapy Methods 0.000 claims description 4
201000008808 Fibrosarcoma Diseases 0.000 claims description 3
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
230000008595 infiltration Effects 0.000 claims description 3
238000001764 infiltration Methods 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
210000000822 natural killer cell Anatomy 0.000 claims description 3
241000193830 Bacillus <bacterium> Species 0.000 claims description 2
229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 2
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 2
241000589516 Pseudomonas Species 0.000 claims description 2
241000187747 Streptomyces Species 0.000 claims description 2
239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 description 143
108090000623 proteins and genes Proteins 0.000 description 92
229940024606 amino acid Drugs 0.000 description 54
102000004169 proteins and genes Human genes 0.000 description 48
235000018102 proteins Nutrition 0.000 description 47
108020004414 DNA Proteins 0.000 description 44
201000011510 cancer Diseases 0.000 description 43
230000006870 function Effects 0.000 description 40
108060003951 Immunoglobulin Proteins 0.000 description 33
239000012636 effector Substances 0.000 description 33
102000018358 immunoglobulin Human genes 0.000 description 33
108090000765 processed proteins & peptides Proteins 0.000 description 32
108091033319 polynucleotide Proteins 0.000 description 31
102000040430 polynucleotide Human genes 0.000 description 31
239000002157 polynucleotide Substances 0.000 description 31
239000013604 expression vector Substances 0.000 description 28
210000004408 hybridoma Anatomy 0.000 description 28
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 25
230000014509 gene expression Effects 0.000 description 24
102000004196 processed proteins & peptides Human genes 0.000 description 24
238000011282 treatment Methods 0.000 description 24
241000699666 Mus <mouse, genus> Species 0.000 description 23
239000013612 plasmid Substances 0.000 description 22
229920001184 polypeptide Polymers 0.000 description 20
230000002829 reductive effect Effects 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 19
241000700605 Viruses Species 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
238000002560 therapeutic procedure Methods 0.000 description 18
230000004083 survival effect Effects 0.000 description 17
-1 IgM Chemical compound 0.000 description 16
125000000539 amino acid group Chemical group 0.000 description 16
239000000243 solution Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 15
238000002965 ELISA Methods 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
230000035772 mutation Effects 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
108010029485 Protein Isoforms Proteins 0.000 description 13
102000001708 Protein Isoforms Human genes 0.000 description 13
238000003556 assay Methods 0.000 description 13
238000012575 bio-layer interferometry Methods 0.000 description 13
238000005516 engineering process Methods 0.000 description 13
241000894007 species Species 0.000 description 13
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 13
230000003612 virological effect Effects 0.000 description 13
206010035226 Plasma cell myeloma Diseases 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
208000024891 symptom Diseases 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
201000000050 myeloid neoplasm Diseases 0.000 description 11
239000008194 pharmaceutical composition Substances 0.000 description 11
238000013518 transcription Methods 0.000 description 11
230000035897 transcription Effects 0.000 description 11
230000004614 tumor growth Effects 0.000 description 11
108091026890 Coding region Proteins 0.000 description 10
102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
238000013507 mapping Methods 0.000 description 10
230000004044 response Effects 0.000 description 10
241001430294 unidentified retrovirus Species 0.000 description 10
102000016289 Cell Adhesion Molecules Human genes 0.000 description 9
108010067225 Cell Adhesion Molecules Proteins 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
241000702421 Dependoparvovirus Species 0.000 description 8
241001529936 Murinae Species 0.000 description 8
108020004511 Recombinant DNA Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
210000004899 c-terminal region Anatomy 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
210000004602 germ cell Anatomy 0.000 description 8
230000003834 intracellular effect Effects 0.000 description 8
210000004962 mammalian cell Anatomy 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
230000002285 radioactive effect Effects 0.000 description 8
230000010076 replication Effects 0.000 description 8
230000014616 translation Effects 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
108700005091 Immunoglobulin Genes Proteins 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000021615 conjugation Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000010369 molecular cloning Methods 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000009257 reactivity Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000007790 solid phase Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000013519 translation Methods 0.000 description 7
239000013603 viral vector Substances 0.000 description 7
101710112752 Cytotoxin Proteins 0.000 description 6
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
229940034982 antineoplastic agent Drugs 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
239000007853 buffer solution Substances 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000008878 coupling Effects 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
239000002619 cytotoxin Substances 0.000 description 6
230000002950 deficient Effects 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
230000036541 health Effects 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
230000028993 immune response Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
238000004806 packaging method and process Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
238000003259 recombinant expression Methods 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
238000011830 transgenic mouse model Methods 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 5
241000713666 Lentivirus Species 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
230000009260 cross reactivity Effects 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
231100000350 mutagenesis Toxicity 0.000 description 5
238000002823 phage display Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000000159 protein binding assay Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 4
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
229940049595 antibody-drug conjugate Drugs 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000000533 capillary isoelectric focusing Methods 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
235000013330 chicken meat Nutrition 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
108700004025 env Genes Proteins 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
229960003330 pentetic acid Drugs 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000026683 transduction Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
206010000060 Abdominal distension Diseases 0.000 description 3
206010069754 Acquired gene mutation Diseases 0.000 description 3
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
102100034349 Integrase Human genes 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241000713869 Moloney murine leukemia virus Species 0.000 description 3
241001494479 Pecora Species 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
241000711975 Vesicular stomatitis virus Species 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000000611 antibody drug conjugate Substances 0.000 description 3
230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
229960003669 carbenicillin Drugs 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
230000006735 deficit Effects 0.000 description 3
229910052805 deuterium Inorganic materials 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000000539 dimer Substances 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000002998 immunogenetic effect Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000007951 isotonicity adjuster Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
238000002515 oligonucleotide synthesis Methods 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000037439 somatic mutation Effects 0.000 description 3
238000012409 standard PCR amplification Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
244000105975 Antidesma platyphyllum Species 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
102100038080 B-cell receptor CD22 Human genes 0.000 description 2
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000713813 Gibbon ape leukemia virus Species 0.000 description 2
239000004366 Glucose oxidase Substances 0.000 description 2
108010015776 Glucose oxidase Proteins 0.000 description 2
229940121672 Glycosylation inhibitor Drugs 0.000 description 2
241000713858 Harvey murine sarcoma virus Species 0.000 description 2
102220605043 Histone H4-like protein type G_K76A_mutation Human genes 0.000 description 2
102220603161 Homeobox protein SIX3_V95P_mutation Human genes 0.000 description 2
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
206010027457 Metastases to liver Diseases 0.000 description 2
206010027458 Metastases to lung Diseases 0.000 description 2
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
101710149951 Protein Tat Proteins 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 2
108010003723 Single-Domain Antibodies Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
230000009830 antibody antigen interaction Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
238000009566 cancer vaccine Methods 0.000 description 2
229940022399 cancer vaccine Drugs 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000004154 complement system Effects 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
229930184221 duocarmycin Natural products 0.000 description 2
229960005501 duocarmycin Drugs 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
101150030339 env gene Proteins 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000005021 gait Effects 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
229940116332 glucose oxidase Drugs 0.000 description 2
235000019420 glucose oxidase Nutrition 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
235000009424 haa Nutrition 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
210000005007 innate immune system Anatomy 0.000 description 2
230000010354 integration Effects 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
238000012004 kinetic exclusion assay Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
108010093470 monomethyl auristatin E Proteins 0.000 description 2
231100000065 noncytotoxic Toxicity 0.000 description 2
230000002020 noncytotoxic effect Effects 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
238000004091 panning Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001566 pro-viral effect Effects 0.000 description 2
230000005180 public health Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
210000003289 regulatory T cell Anatomy 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
102220006123 rs1042713 Human genes 0.000 description 2
102220269348 rs61747367 Human genes 0.000 description 2
102220075759 rs796052400 Human genes 0.000 description 2
238000013391 scatchard analysis Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
231100000617 superantigen Toxicity 0.000 description 2
238000012353 t test Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
MNFPZBOQEWMBOK-UHFFFAOYSA-N AS-I-145 Chemical compound C1=CC=CC2=C(CCCl)C(NC(=O)C3=CC=4C=C(C(=C(OC)C=4N3)OC)OC)=CC(N)=C21 MNFPZBOQEWMBOK-UHFFFAOYSA-N 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
206010006220 Breast cyst Diseases 0.000 description 1
206010006272 Breast mass Diseases 0.000 description 1
206010006298 Breast pain Diseases 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100037904 CD9 antigen Human genes 0.000 description 1
101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
241000195628 Chlorophyta Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000003915 DNA Topoisomerases Human genes 0.000 description 1
108090000323 DNA Topoisomerases Proteins 0.000 description 1
239000012626 DNA minor groove binder Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
108050003188 Disks large-associated protein 1 Proteins 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108091006020 Fc-tagged proteins Proteins 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000021309 Germ cell tumor Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000034507 Haematemesis Diseases 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010023804 Large intestine perforation Diseases 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
108010031034 MHC class I-related chain A Proteins 0.000 description 1
108010086911 MICB antigen Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
208000006662 Mastodynia Diseases 0.000 description 1
229930126263 Maytansine Natural products 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
240000002769 Morchella esculenta Species 0.000 description 1
235000002779 Morchella esculenta Nutrition 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
102000005717 Myeloma Proteins Human genes 0.000 description 1
108010045503 Myeloma Proteins Proteins 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108091005461 Nucleic proteins Chemical group 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
206010034811 Pharyngeal cancer Diseases 0.000 description 1
241000235648 Pichia Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
229940079156 Proteasome inhibitor Drugs 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
201000003761 Vaginal carcinoma Diseases 0.000 description 1
206010046910 Vaginal haemorrhage Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000012410 cDNA cloning technique Methods 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
229930195731 calicheamicin Natural products 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000004106 carminic acid Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
210000001100 crypt cell Anatomy 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
NVLDXKCJZRQSDJ-UHFFFAOYSA-L cyclohexane-1,2-diamine;2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-olate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.OCC(O)C1OC(=O)C([O-])=C1O.OCC(O)C1OC(=O)C([O-])=C1O NVLDXKCJZRQSDJ-UHFFFAOYSA-L 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
229930188854 dolastatin Natural products 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000007937 eating Effects 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940096118 ella Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
LNBHUCHAFZUEGJ-UHFFFAOYSA-N europium(3+) Chemical compound [Eu+3] LNBHUCHAFZUEGJ-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
201000001343 fallopian tube carcinoma Diseases 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000006481 glucose medium Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000035861 hematochezia Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
239000003276 histone deacetylase inhibitor Substances 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
125000005597 hydrazone group Chemical group 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
108091008915 immune receptors Proteins 0.000 description 1
102000027596 immune receptors Human genes 0.000 description 1
229940045207 immuno-oncology agent Drugs 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
239000002584 immunological anticancer agent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
210000003071 memory t lymphocyte Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000012900 molecular simulation Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
210000000581 natural killer T-cell Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
230000017511 neuron migration Effects 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
230000030147 nuclear export Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
229940120723 recombinant human hyaluronidase Drugs 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
102200097283 rs199472833 Human genes 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012128 staining reagent Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
HKCRVXUAKWXBLE-UHFFFAOYSA-N terbium(3+) Chemical compound [Tb+3] HKCRVXUAKWXBLE-UHFFFAOYSA-N 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
208000013013 vulvar carcinoma Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)

CA3104252A 2018-06-29 2019-06-27 Anti-l1cam antibodies and uses thereof Pending CA3104252A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
KR1020180075955A KR20200002451A (ko)	2018-06-29	2018-06-29	인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR10-2018-0075955		2018-06-29
US201962865871P	2019-06-24	2019-06-24
US62/865,871		2019-06-24
PCT/IB2019/055472 WO2020003210A1 (en)	2018-06-29	2019-06-27	Anti-l1cam antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
CA3104252A1 true CA3104252A1 (en)	2020-01-02

Family

ID=69154626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3104252A Pending CA3104252A1 (en)	2018-06-29	2019-06-27	Anti-l1cam antibodies and uses thereof

Country Status (6)

Country	Link
JP (1)	JP2021529776A (ja)
KR (2)	KR20200002451A (ja)
CN (1)	CN112689644A (ja)
AU (1)	AU2019293530A1 (ja)
CA (1)	CA3104252A1 (ja)
SG (1)	SG11202012680TA (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2024100200A1 (en) *	2022-11-09	2024-05-16	Cis Pharma Ag	Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023078224A1 (zh) *	2021-11-03	2023-05-11	同润生物医药(上海)有限公司	新型抗l1cam抗体
CN115078738A (zh) *	2022-06-30	2022-09-20	复旦大学	一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用
WO2024088283A1 (zh) *	2022-10-26	2024-05-02	同润生物医药(上海)有限公司	人源化的l1cam抗体药物偶联物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007114550A1 (en) *	2006-04-03	2007-10-11	Korea Research Institute Of Bioscience And Biotechnology	A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
KR101501736B1 (ko) *	2008-12-05	2015-03-12	한국생명공학연구원	인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
KR102058381B1 (ko) *	2012-08-24	2019-12-24	강원대학교산학협력단	인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
KR101504039B1 (ko) *	2012-11-16	2015-03-19	강원대학교산학협력단	인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도

2018
- 2018-06-29 KR KR1020180075955A patent/KR20200002451A/ko unknown
2019
- 2019-06-27 CA CA3104252A patent/CA3104252A1/en active Pending
- 2019-06-27 CN CN201980045545.5A patent/CN112689644A/zh active Pending
- 2019-06-27 AU AU2019293530A patent/AU2019293530A1/en active Pending
- 2019-06-27 JP JP2020573334A patent/JP2021529776A/ja active Pending
- 2019-06-27 SG SG11202012680TA patent/SG11202012680TA/en unknown
- 2019-06-27 KR KR1020217003012A patent/KR20210042091A/ko unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2024100200A1 (en) *	2022-11-09	2024-05-16	Cis Pharma Ag	Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications

Also Published As

Publication number	Publication date
SG11202012680TA (en)	2021-01-28
AU2019293530A1 (en)	2021-01-21
KR20210042091A (ko)	2021-04-16
JP2021529776A (ja)	2021-11-04
CN112689644A (zh)	2021-04-20
KR20200002451A (ko)	2020-01-08

Legal Events

Date	Code	Title	Description
2022-08-17	EEER	Examination request	Effective date: 20220627
2023-05-09	EEER	Examination request	Effective date: 20220627
2023-06-06	EEER	Examination request	Effective date: 20220627
2023-10-05	EEER	Examination request	Effective date: 20220627
2024-05-10	EEER	Examination request	Effective date: 20220627

Publication	Publication Date	Title
US20230105714A1 (en)	2023-04-06	Anti-tim-3 antibodies and compositions
CN108738324B (zh)	2022-06-21	抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
TWI758928B (zh)	2022-03-21	抗cd73抗體及其用途
US11034765B2 (en)	2021-06-15	Anti-PD-1 antibodies and compositions
CN107001476B (zh)	2021-08-24	用于增强的免疫应答和癌症治疗的组合物和方法
TWI806873B (zh)	2023-07-01	特異性結合pd-1之抗體及使用方法
AU2022228155A1 (en)	2022-11-10	Antibodies to cd40
US20180355043A1 (en)	2018-12-13	Antibodies Specifically Binding HLA-DR and Their Uses
BR112020023508A2 (pt)	2021-03-30	Anticorpos anti-cd3 e usos dos mesmos
CA3104252A1 (en)	2020-01-02	Anti-l1cam antibodies and uses thereof
AU2015228454A1 (en)	2016-08-11	Anti-MCAM antibodies and associated methods of use
CA3128104A1 (en)	2020-08-06	Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
BR112020005402A2 (pt)	2020-09-29	anticorpos, sequências de polinucleotídeo e de ácido nucleico, vetores, célula hospedeira, métodos de expressar o anticorpo e de modulação conjugado, composição farmacêutica, métodos para tratar uma doença, para detectar, para diagnosticar e para estimular uma resposta imune, método in vivo ou in vitro, uso, receptor de antígeno quimérico e célula t
KR20220057558A (ko)	2022-05-09	항-cd73 항체
JP2022530404A (ja)	2022-06-29	Ｃｄ７３遮断抗体
JP2024012682A (ja)	2024-01-30	抗ｌ１ｃａｍ抗体及びその使用
WO2022212876A1 (en)	2022-10-06	Antibodies against cleaved cdcp1 and uses thereof
US20210284734A1 (en)	2021-09-16	Anti-pd-1 antibodies and compositions
CA3183389A1 (en)	2022-01-06	Bispecific antibody and use thereof
CA3181591A1 (en)	2021-11-04	Antibodies specific to abcb5 and uses thereof
WO2018059465A1 (zh)	2018-04-05	抗cd27抗体、其抗原结合片段及其医药用途
KR20200103761A (ko)	2020-09-02	항-cd40 항체 및 그의 용도
KR102671348B1 (ko)	2024-05-30	Cd40에 대한 항체
JP2023536630A (ja)	2023-08-28	Ｐｄ－ｌ１結合性作用剤およびその使用
KR20230157970A (ko)	2023-11-17	항-vista 항체 및 이의 용도

CA3104252A1 - Anti-l1cam antibodies and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=69154626

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (3)

Family Cites Families (4)

Cited By (1)

Also Published As

Similar Documents

Legal Events